1-31-08
FORTICELL BIOSCIENCE CHIEF EXECUTIVE OFFICER INTERVIEWED ON CEOCAST.COM

1-22-08
WALLST.NET ANNOUNCES UPCOMING INTERVIEW WITH PRESIDENT OF FORTICELL BIOSCIENCE

1-14-08
FORTICELL BIOSCIENCE ANNOUNCES COLLABORATION AGREEMENT WITH CJ CHEILJEDANG, A KOREAN PHARMACEUTICAL GIANT TO USE FIBRIN MICROBEADS (FMB) FOR NOVEL UMBILICAL CORD BLOOD STEM CELL RECOVERY

1-9-08
ORTEC SHAREHOLDERS APPROVE CORPORATE NAME CHANGE TO FORTICELL BIOSCIENCE, INC.

12-5-07
ORTEC SELECTED TO PRESENT AMONG LEADING LIFE SCIENCE COMPANIES AT NEW YORK SOCIETY OF SECURITY ANALYSTS CONFERENCE

10-23-07
ORTEC FILES PMA FOR ORCEL® FOR VLU INDICATION

7-11-07
DR. COSTA PAPASTEPHANOU APPOINTED CEO - Three New Board Members Added -

6-20-07
Ortec Announces $8.7 Million Private Placement in Conjunction with Agreement to Exchange $43 Million Liability for $10 Million of Convertible Preferred Stock

2-26-07
Ortec Initiates Pre Market Approval (PMA) Application Filing Seeking Approval for OrCel® in Treating Venous Leg Ulcers

11-29-06
Ortec and Paul Capital Healthcare to Restructure Existing Financing Agreement

9-29-06
FDA Issues Approvable Letter to Ortec for Use of Cryopreserved OrCel in EB Patients' Hand Reconstructions and Donor Sites

9-20-06
Ortec Obtains Second Patent Allowance on Haptide Cell Attchment Technology

9-12-06
Ortec Announces Positive Results in Confirmatory Venous Leg Ulcer Trial

8-3-06
Ortec’s FDA Approved Cell Line Plays Pivotal Role in Creation of First Embryonic Stem Cell Lines Fit for Human Clinical Trials

7-24-06
Ortec Announces Reverse Stock Split

7-6-06
Ortec Issues Update on Its Three Technology Platforms for Regenerative Medicine and Stem Cells

6-22-06
Ortec Initiates Pre-Clinical Animal Study to Evaluate Fibrin Microbead Technology for Stem Cell Regeneration of Non-Union Bone Defects

6-20-06
Ortec to be Granted European Patent on its Fibrin Microbead Enabling Technology for Stem Cell ™ Isolation and Therapy

6-1-06
Ortec Obtains First U.S. Patent allowance on Haptide™ Cell Attachment Technology

5-30-06
Ortec Expects to File HDE Application with FDA Requesting Marketing Approval of Cryo OrCel® for Use in EB Patients

5-23-06
Ortec CEO Details Corporate Vision and Mission in Letter to Shareholders.

5-16-06
Animal Studies Show Ortec's Fibrin Microbeads Recover up to Four Times the Number of Stem Cells as Conventional Methods

5-10-06
Results Showing the Ability of Ortec's Fibrin Microbeads Technology to Isolate Adult Stem cells from Blood Published in Bone Marrow Transplantation Journal

4-25-06
Ortec Completes Patient Enrollment for Confirmatory Trial Evaluating OrCel in Healing Venous Ulcers